BONE MARROW TRANSPLANTATION
Scope & Guideline
Leading the Charge in Cutting-edge Transplantation Research.
Introduction
Aims and Scopes
- Hematopoietic Stem Cell Transplantation (HSCT):
The journal emphasizes research on the efficacy, safety, and outcomes of HSCT for various hematological disorders, including leukemia, lymphoma, and myelodysplastic syndromes. This encompasses studies on conditioning regimens, donor selection, and post-transplant care. - Graft-versus-Host Disease (GVHD):
A significant part of the journal's focus is on the prevention, diagnosis, and treatment of GVHD, a common complication following HSCT. This includes exploring novel prophylactic strategies and therapies for managing acute and chronic GVHD. - Innovative Therapies and Techniques:
Research on novel cellular therapies such as CAR-T cell therapy, as well as advancements in immunotherapy and targeted therapies, is frequently published, reflecting the journal's commitment to integrating new treatment modalities into clinical practice. - Infectious Complications and Management:
The journal addresses the challenges of infectious complications in HSCT recipients, including the management of viral reactivations (e.g., CMV, EBV) and bacterial infections, highlighting the importance of prophylactic strategies and treatment protocols. - Patient-Centered Care and Quality of Life:
Studies examining the psychosocial aspects, quality of life, and long-term outcomes of patients undergoing HSCT are also a critical focus, emphasizing the holistic approach to patient care.
Trending and Emerging
- Post-Transplant Cyclophosphamide (PTCy):
There is a growing body of research dedicated to the use of PTCy as a prophylactic treatment in haploidentical stem cell transplantation, highlighting its effectiveness in reducing GVHD and improving transplant outcomes. - CAR-T Cell Therapy:
The ongoing exploration of CAR-T cell therapy in various hematological malignancies, particularly in relapsed or refractory cases, is a prominent theme, showcasing its integration into transplantation protocols. - Patient Engagement and Quality of Life Research:
An increasing focus on patient-reported outcomes and quality of life in HSCT recipients signifies a shift towards more patient-centered research, emphasizing the importance of psychosocial factors in treatment success. - Microbiome Research in Transplantation:
Emerging studies investigating the role of gut microbiota in transplant outcomes and GVHD are gaining traction, reflecting a broader interest in the interplay between microbiome health and patient recovery. - Use of Advanced Imaging and Biomarkers:
The integration of advanced imaging techniques and biomarker research to predict outcomes post-transplantation is becoming more common, enhancing the ability to tailor treatments to individual patient needs.
Declining or Waning
- Traditional Conditioning Regimens:
There is a noticeable decrease in studies focused solely on traditional myeloablative conditioning regimens as researchers increasingly explore reduced-intensity and non-myeloablative approaches, which are becoming more favored in practice. - Single Donor Transplantation Studies:
Research focusing on single donor transplantation models, particularly in less diverse donor settings, is becoming less common as the field shifts towards exploring haploidentical and mismatched donor strategies, which are gaining traction. - Basic Science Studies on Stem Cell Biology:
There seems to be a waning interest in basic science research solely focused on stem cell biology without direct clinical applications, as more research is geared towards translational studies and clinical outcomes. - Longitudinal Studies with Limited Sample Sizes:
The frequency of longitudinal studies with small sample sizes appears to be decreasing, as there is a growing emphasis on larger, multicenter studies that offer more robust data and generalizable findings.
Similar Journals
Mediterranean Journal of Hematology and Infectious Diseases
Fostering innovation in medical research for a healthier tomorrow.Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.
Transplantation and Cellular Therapy
Pioneering Research for Tomorrow's Medical Breakthroughs.Transplantation and Cellular Therapy is a leading journal published by Elsevier Science Inc, dedicated to advancing the fields of transplantation, immunology, cell biology, and molecular medicine. With its ISSN of 2666-6375 and E-ISSN 2666-6367, this journal serves as a vital resource for researchers, practitioners, and students aiming to stay at the forefront of innovative therapies and clinical practices in transplantation. As of 2023, it holds an impressive Q1 ranking in multiple categories, including Cell Biology, Hematology, Immunology and Allergy, Molecular Medicine, and Transplantation, reflecting its high impact and relevance in the scientific community. The journal, operating from its base in the Netherlands, supports Open Access publishing to enhance the dissemination and accessibility of groundbreaking research. Acknowledging the significance of transplantation and cellular therapies in modern medicine, Transplantation and Cellular Therapy is poised to propel future discoveries and developments in these critical domains.
INTERNATIONAL JOURNAL OF HEMATOLOGY
Navigating the Future of Blood Health ResearchThe INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.
Experimental Hematology & Oncology
Empowering Discovery in Hematology and OncologyExperimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.
Current Research in Translational Medicine
Catalyzing Change in the Landscape of Translational MedicineCurrent Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.
HAEMATOLOGICA
Pioneering Research in Hematology for Tomorrow's AdvancementsHAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.
JOURNAL OF CLINICAL IMMUNOLOGY
Innovating Therapeutic Strategies for Immune HealthJOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.
EUROPEAN JOURNAL OF HAEMATOLOGY
Innovative Insights into Blood Health and DiseaseEUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.
Transplant Infectious Disease
Exploring the complexities of infectious challenges in transplant medicine.Transplant Infectious Disease is a premier journal dedicated to advancing the understanding of infectious complications in transplant recipients, contributing significantly to the fields of Infectious Diseases and Transplantation. Published by Wiley in the United Kingdom, this journal boasts an impressive reputation within the academic community, holding a 2023 Q2 quartile ranking in both Infectious Diseases and Transplantation, as well as notable Scopus rankings that position it among the top tiers of its categories. With a convergence of scholarly articles and research findings from 1999 through 2024, Transplant Infectious Disease serves as a critical resource for researchers, professionals, and students seeking to explore the intersection of transplantation and infectious diseases. The journal encourages open dialogue and knowledge dissemination through rigorous peer-reviewed content, making it an essential platform for those aiming to address the challenges and innovations in transplant medicine.
AMERICAN JOURNAL OF HEMATOLOGY
Empowering Discoveries in Blood DisordersAmerican Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.